Â鶹´«Ã½¸ßÇå

Tzield, which was approved by the FDA in 2022, is the first drug on the market indicated to delay the full onset of Type 1 Diabetes. This novel drug is available for patients in Stage-2  Type 1 Diabetes as a 1-day infusion series. As part of its ongoing commitment diabetes treatment and prevention, the Barbara Davis Center was the first site in Â鶹´«Ã½¸ßÇå to infuse a patient with Tzield. The Center's new Early T1D Clinic now offer this therapy in addition to screening, monitoring, long-term follow-up, and education as patients navigate the onset of T1D.

Dr. Garg joined CBS Â鶹´«Ã½¸ßÇå to discuss insulin prices and why it's time manufacturers work on driving down prices.

In a randomized clinical trial including 88 children and adolescents with newly diagnosed type 1 diabetes, C-peptide levels (a measure of pancreatic beta cell function) measured during a mixed-meal tolerance test 52 weeks after diagnosis were 30% higher with verapamil compared with placebo. The percentage of participants with a 52-week peak C-peptide level of 0.2 pmol/mL or greater was 95% in the verapamil group vs 71% in the placebo group. Verapamil had few adverse events.

In a randomized clinical trial including 113 youths aged 7 to 17 years with newly diagnosed type 1 diabetes, there was no significant difference in C-peptide levels measured during a mixed-meal tolerance test (a measure of pancreatic beta cell function) 52 weeks after diagnosis between intensive management and standard care groups. Mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% with intensive management, which included automated insulin delivery, compared with 64% with standard care.

Mia Smith's, DVM, PhD, interest in researching Diabetes and B cells all started with her love of animals. Her furry patients would come to the veterinary office sick from autoimmune conditions, disorders that trigger the body’s immune system to attack itself.

“Dogs can get many autoimmune disorders that are similar to humans – diabetes, lupus, autoimmune thyroid disease,”

With this in mind, Smith began researching diabetes and B cells – a type of immune cell – in search of preventative therapies for autoimmune conditions in both humans and their four-legged friends, conducting her research at the Barbara Davis Center for Diabetes. 

In 2022, Dr. Smith sat down with the CU Anschutz media team to discuss B cell research and how these cells, along with genetics, impacts the onset of Type 1 Diabetes.

Dr. Laurel Messer discussed the impacts on young people of feeling more engaged with their diabetes management. The findings were from a 2-week observational study of adolescents with Type 1 Diabetes that analyzed the biopsychosocial factors that could influence daily engagement with managing T1D.

Dr Marian Rewers discussed new research that indicates a lack of association between infection with SARS-CoV-2 and development of Type 1 Diabetes. The study, which the Barbara Davis Center collaborated on, screened 50,000 youths across both Â鶹´«Ã½¸ßÇå and Bavaria, Germany to evaluate to potential that Covid-19 may trigger an autoimmune response that leads to development of T1D.